EHA 2018: The Issue of Frailty in MM
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
When treating patients with MM frail patients are less able to tolerate aggressive treatment and therefore have poorer OS. In the era of novel agents there is a… read more.
The growing number of novel treatments for multiple myeloma (MM) means that more patients can achieve the therapeutic goal of a deep and prolonged first remission – in… read more.
Gene expression profiling has shown that that the activated B-cell and germinal centre B-cell subtypes of diffuse large B-cell lymphoma are driven by different oncogenic pathways and this may… read more.
In the video, Dr Cathy Burton (Leeds), Dr Stella Bowcock (London) and Dr Stephen Robinson (Bristol) give their highlights from this year’s BSH meeting, including the Lymphoma Specialist Interest Group (SIG) which held a… read more.
BEACOPP treatment offers considerable advantages in terms of overall survival and low dose regimens offer short, safe and effective treatment for newly-diagnosed advanced-stage HL patients ……
The launch of biosimilar rituximab provided an opportunity to save £300,000 per year but called for time-consuming intravenous administration that exceeded the capacity of the hospital unit. Off-site… read more.
Is CAR-T cell therapy a realistic treatment option for patients with large B cell lymphoma who otherwise have no curative options or an expensive new treatment that is… read more.
Cancer drugs receive special funding in the NHS but it is not automatic and input from expert clinicians is essential to ensure that effective treatments are funded appropriately…. read more.
Dendritic cells (DC) are known to play an important role in the initiation of primary immune responses. In cancer, deficient DCs contribute to tumour-associated immune tolerance. Functionally active… read more.
Dr Martin Kaiser (London) discusses recent work from the UK on identifying robust markers and how clinical decisions can be made according to the biology of the disease. Advances… read more.
Professor Paul G. Richardson MD (R.J. Corman Professor, Medicine, Harvard Medical School, Boston, USA) and Dr Karthik Ramasamy (Oxford Oncology and Haematology Centre) discuss important learnings from real-world… read more.
There were lots of updates from various studies in myeloma at ASH 2017. Above, Professor Sagar Lonial (Emory University School of Medicine, Atlanta, GA) discusses data presented showing… read more.
Advertisment
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.